ClinicalTrials.gg
CompletedNCT07230171Updated Oct 30, 2026

The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia

An interventional study of Pregabalin and venlafaxine concomitant therapy and Esketamine plus pregabalin and venlafaxine concomitant therapy in Fibromyalgia, Pregabalin and Esketamine, sponsored by Beijing Tiantan Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Fibromyalgia with a site in China — 14 open to participants now, 14 under way, none of them phase 3. Fibromyalgia · China.

Enrollment
15th of 23
92 · median 120
Started
2025
with 9 others
No phase
19 of 29
10 open now
Registered
23rd of 29
by date
Lead sponsor
8 of 29
Beijing Tiantan Hospital

Among the 29 studies in Fibromyalgia with a site in China, this one is the 15th largest by enrollment of the 23 interventional ones that give a count, is one of 10 that started in 2025, is one of 19 with no phase, and was the 23rd registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

14 of the 29 studies in Fibromyalgia with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Fibromyalgia with a site in China, or all of them as a file.
02

Study summary

Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy when standard treatments are insufficient remains unclear.

03

Conditions studied

  • Fibromyalgia
  • Pregabalin
  • Esketamine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between ages over 18 years with proper cognitive function and language skills for the study;
  • Patients diagnosed with FM as defined by the ACR FM diagnostic criteria;
  • Patients who have experienced insufficient symptom relief with non-pharmacological treatments and have not previously received recommended pharmacological treatment for FM;
  • A score of ≥ 4 on the average pain intensity over 7 days on the numeric rating scale (NRS) at baseline.

Exclusion criteria

Exclusion criteria:

  • Patient refusal;
  • Inability to sign ;
  • Had other secondary FM, this is, hypothyroidism, nutritional deficiency, diabetes mellitus, connective tissue disorder;
  • Had psychiatric disorder, this is, schizophrenia and other psychotic disorder, bipolar disorder, or personality disorder;
  • Obstructive sleep apnea syndrome or a STOP-Bang score ≥ 3;
  • History of treatment with pregabalin and/or venlafaxine for any disease;
  • History of treatment with intravenous ketamine or ESK for chronic pain;
  • Presence of other painful ailments such as inflammatory rheumatic disease;
  • Uncontrolled diabetes, hypertension, , narrow-angle glaucoma, hyperthyroidism, severe cardiovascular disease or any other to esketamine;
  • History of prescription drug abuse, alcoholism or illicit drug use;
  • Pregnant or lactating women;
  • Allergic to any of the study drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Active comparator
    Control group

    Pregabalin and venlafaxine concomitant therapy

    Drug: Pregabalin and venlafaxine concomitant therapy

  • Experimental
    Treatment group

    Esketamine plus pregabalin and venlafaxine concomitant therapy

    Drug: Esketamine plus pregabalin and venlafaxine concomitant therapy

Interventions

  • DrugPregabalin and venlafaxine concomitant therapy

    The control group will only receive an increased dosage of pregabalin and venlafaxine regimen. Each participant will be instructed with the same dose escalation regimen, until they reach the maximal tolerated dose (MTD) or the ceiling dose or the maximum daily recommended dose. The maximum recommended daily dose of pregabalin was 450 mg and venlafaxine was 225 mg.

  • DrugEsketamine plus pregabalin and venlafaxine concomitant therapy

    The treatment group, in addition to the increased pregabalin and venlafaxine medication dosage regimen, will also receive a single intravenous infusion of esketamine on the day of enrollment. Plasma concentrations of esketamine and its metabolites will be measured at the end of infusion to enable a limited characterization of systemic exposure and to support exploratory exposure-response analyses. Each participant will be instructed with the same dose escalation regimen, until they reach the maximal tolerated dose (MTD) or the ceiling dose or the maximum daily recommended dose. The maximum recommended daily dose of pregabalin was 450 mg and venlafaxine was 225 mg.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the mean pain intensity

    This outcome is calculated as the average of daily 24-hour pain intensity scores recorded in patient diaries over 7 consecutive days using NRS.

    Time frame: At the week 1.

Secondary outcomes

  1. Average pain intensity

    The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: At the weeks 1, 2, 4, 8, and 12

  2. Proportion of patients achieving pain reduction at 50%;

    The proportion of patients achieving a ≥ 50% reduction in mean baseline pain intensity. The pain intensity will be measured based on NRS, where 0 represents no pain and 10 represents worst pain imaginable.

    Time frame: at weeks 1, 2, 4, 8, and 12

  3. The median pain relief time

    The median pain relief time, defined as the time of 50% decrease in NRS score from baseline. Pain intensity will be measured using the NRS, where 0 indicates no pain, and 10 represents the worst imaginable pain.

    Time frame: Through study completion, an average of 12 weeks

  4. The Revised FM Impact Questionnaire (FIQR)

    The FIQR is used to assessed health status and functional disablity. FIQR is a 21-item self-administered questionnaire, based on symptoms reported within the preceding 7 days. FIQR total score ranges from 0 to 100, with higher values indicating worse health status.

    Time frame: At the weeks 4, 8, and 12

  5. Hospital Anxiety and Depression scale (HADS)

    The HADS is used to assess anxiety (7 items) and depression (7 items). Scores range from 0 to 21 on each subscale, with higher scores indicating worse symptomatology.

    Time frame: At the weeks 4, 8, and 12

  6. The short-form 36 Health Survey (SF-36)

    The SF-36 assesses health-related quality of life, capturing preferences across various health states. It assesses 8 dimensions: physical functioning, physical role limitations due to physical health, bodily pain, general health, vitality, social functioning, emotional role limitations due to emotional problems, and mental health. Scores range from 0 to 100 for each dimension, with higher scores indicating better health status.

    Time frame: At the weeks 4, 8, and 12

  7. Multidimensional Fatigue Inventory (MFI)

    Fatigue is evaluated using the MFI, a 20-item assessment tool with five domains. Higher scores indicate a higher degree of fatigue.

    Time frame: At the weeks 4, 8, and 12

  8. Medical Outcomes Study Sleep Scale (MOS)

    The MOS is a questionnaire comprising 12 items that assess various aspects of sleep using a 6-point ordinal scale (1 indicating permanence and 6 indicating absence).

    Time frame: At the weeks 4, 8, and 12

  9. The doses of pregabalin and venlafaxine

    Time frame: at weeks 1, 2, 4, 8, and 12

  10. Adverse events

    Time frame: Through study completion, an average of 12 weeks

07

Study locations

1 site
  • Beijing Tiantan Hospital, Beijing, Beijing 100070
    Beijing, China
08

References and documents

Publications

  • Shrestha N, Liu M, Niu S, Cheng H, Sun Y, Mei S, Luo F. Efficacy and Safety of Adjunctive Therapy Using Single High-Dose S-Ketamine Infusion for Fibromyalgia: A Multicenter, Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Study Protocol. J Pain Res. 2026 May 16;19:598907. doi: 10.2147/JPR.S598907. eCollection 2026. PubMed 42170615 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures and appendices) are available. Derived data supporting the findings of this study are available from the corresponding author Fang Luo on request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jun 2026, 8 months.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 8 months is below that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Jun 2027 → Jun 2026 and completion Aug 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Sep 15, 2025
Primary completionActual
Jun 14, 2026was Jun 2027
CompletionActual
Aug 30, 2026was Aug 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Primary completion
Jun 30, 2027→Jun 14, 2026 (actual)
Oct 30, 2026
Study completion
Aug 31, 2027→Aug 30, 2026 (actual)
Oct 30, 2026
Secondary outcomes
2 edited, 2 removed
What changed in the outcomes
  • EditedProportion of patients achieving pain reduction at 50% and 30%;Time frame: at weeks 1, 2, 4, 8, and 12
  • EditedThe maximal tolerated doses of pregabalin and venlafaxineTime frame: at weeks 1, 2, 4, 8, and 12
  • RemovedWorst pain intensityTime frame: at weeks 1, 2, 4, 8, and 12
  • RemovedPlasma concentrations of esketamine and its metabolites at the end of infusionTime frame: At the end of esketamine infusion, that is at day 0
Oct 30, 2026
Sponsor
Collaborators added: Beijing Jianjia Rehabilitation Hospital·Beijing General Aerospace Hospital·Yangyuan Youyi Hospital
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2027→Jun 14, 2026 (now actual)
    Study completion Aug 31, 2027→Aug 30, 2026 (now actual)
    Secondary outcomes 2 edited, 2 removed
    What changed in the outcomes
    • EditedProportion of patients achieving pain reduction at 50% and 30%;Time frame: at weeks 1, 2, 4, 8, and 12
    • EditedThe maximal tolerated doses of pregabalin and venlafaxineTime frame: at weeks 1, 2, 4, 8, and 12
    • RemovedWorst pain intensityTime frame: at weeks 1, 2, 4, 8, and 12
    • RemovedPlasma concentrations of esketamine and its metabolites at the end of infusionTime frame: At the end of esketamine infusion, that is at day 0
    Sponsor Collaborators added: Beijing Jianjia Rehabilitation Hospital·Beijing General Aerospace Hospital·Yangyuan Youyi Hospital
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07230171
Collaborators
Beijing Ditan Hospital, Beijing Sanbo Brain Hospital, Beijing Rehabilitation Hospital, Beijing General Aerospace Hospital, Yangyuan Youyi Hospital
Responsible party
Fang Luo (Director, Department of Pain Management, Principal Investigator, Clinical Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Nov 17, 2025
Start date
Sep 15, 2025
Primary completion
Jun 14, 2026
Completion
Aug 30, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion